Performance and Tolerability of the Moisturizers Cetaphil® and Excipial® in Atopic Dermatitis: What is the Evidence Based on Randomized Trials?

Esther J. van Zuuren, Zbys Fedorowicz, Bernd W. M. Arents
  • Dermatology and Therapy, June 2017, Springer Science + Business Media
  • DOI: 10.1007/s13555-017-0184-3

What is it about?

INTRODUCTION: Moisturizers play a prominent role in the management of atopic dermatitis by improving the impaired skin barrier function and enhancing skin hydration. Their efficacy was evaluated in a recently published Cochrane Review 'Emollients and moisturizers for eczema'. OBJECTIVE: In the present review, we summarize the performance and safety of Cetaphil® and Excipial® moisturizing products. METHODS: This review was carried out in compliance with standard Cochrane methodological procedures, which means independent study selection, data extraction, assessment of risk of bias, and analyses by two review authors. The quality of evidence for the predefined outcomes was rated with the GRADE approach. The prespecified outcomes of the review included participant assessments, satisfaction, adverse events, investigator assessments, prevention of flares, change in use of topical active treatment, skin barrier function and quality of life. RESULTS: Four randomized controlled studies examining these moisturizers were included in the previously published Cochrane Review. For the performance and tolerability of these moisturizers, there was very low to moderate quality evidence for the prespecified outcomes. CONCLUSION: The results from these four studies are in line with those of the Cochrane Review that moisturizers themselves have beneficial effects, and that combining moisturizers with active topical treatment produced better results when compared to active topical treatment alone

Read Publication

http://dx.doi.org/10.1007/s13555-017-0184-3

The following have contributed to this page: Dr Esther J van Zuuren and Dr Zbys Fedorowicz